Annual Drug Patent Expirations for LINZESS
Linzess is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for LINZESS.
This drug has one hundred and eigthy-four patent family members in forty-two countries.
The generic ingredient in LINZESS is linaclotide. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
